LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Back again in this hot Italian summer. Here we go with some more good news! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. […]
MVB-101 (aka CBP-1018) is a new clinical-stage drug conjugate for prostate cancer simultaneously targets PSMA and folate receptor alpha (FRα) to overcome tumor heterogeneity. The drug is a bivalent peptide-like drug conjugate roughly one-fiftieth the size of a traditional antibody drug conjugate, designed to diffuse more rapidly into solid tumors. It delivers monomethyl auristatin E […]
The RIALTO trial challenges decades of oncology dogma that treating the prostate becomes irrelevant once cancer spreads. For patients with de novo metastasized prostate cancer who show incomplete PSA-response (PSA >0.2 ng/ml after six months of combined ADT+ARPI), the prostate may function as a persistent tumor reservoir continuously seeding metastases. Local radiotherapy to the prostate […]
A major advancement in metastatic hormone-sensitive prostate cancer has emerged from the ENZAMET trial: analysis using the Decipher genomic classifier shows that men with very high-risk tumor profiles benefit significantly from adding docetaxel to standard hormone therapy. Patients with a Decipher score above 0.85 who received the triplet regimen (ADT plus enzalutamide plus docetaxel) had […]
A single infusion of a CRISPR-based therapy has significantly reduced attacks in patients with hereditary angioedema (HAE) in what appears to be the first successful Phase III trial of an in vivo gene-editing treatment. The findings, presented at a major European congress and published in the New England Journal of Medicine, mark a turning point […]
For years, advanced prostate cancer has been the textbook example of an “immunologically cold” tumor: it doesn’t provoke a strong immune response, carries few mutations that help the immune system recognize cancer, and is packed with cells that actively suppress immunity. Because of this, immune checkpoint inhibitors have largely failed in this disease. Against this […]
Cancer therapy has a persistent blind spot. Tumors shrink, biomarkers improve, scans look clean—and yet relapse remains common. The reason is often a tiny population of surviving cells known as persisters. These cells are not genetically resistant. They are identical to the bulk tumor but enter a transient, drug-tolerant state that allows them to survive […]
The phase III PrTK03 trial, reported in The Lancet Oncology, demonstrates that adding aglatimagene besadenovec (CAN-2409) plus valacyclovir to standard radiotherapy improves disease-free survival in patients with localized prostate cancer. Aglatimagene is an intratumoral adenoviral gene therapy that delivers the HSV-tk gene, enabling tumor cells to convert the prodrug valacyclovir into a cytotoxic metabolite that […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Next week I’ll be traveling a bit, but I’ll do my best to keep posting and prepare the next newsletter. For now, here are this week’s news. Stay strong and fight on! As usual, we also have a podcast […]
61Cu-NU101 is a new PSMA-targeted PET/SPECT tracer for prostate cancer that showed promise in phase 1, detecting more lesions than 18F-piflufolastat (Pylarify) in half of the 8 patients studied, with lower background uptake and no side effects. The key advantage is its 3.3-hour half-life, compared to 68 minutes for 68Ga-PSMA-11 and 109 minutes for 18F-piflufolastat. […]